Vimta Labs Ltd
Vimta Labs Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Vimta Labs is confident about good near-term and long-term growth due to favorable markets in pharma, food testing, preclinical and clinical research, and electronics testing. Vimta Labs expresses confidence in continued growth driven by favorable market conditions across pharma, food testing, and electronics sectors. - The company targets INR 500 crores revenue for the next fiscal year but refrains from providing firm forward-looking guidance. - EBITDA margins expected to maintain near current levels (±1-2%) with ongoing digital transformation and AI integration supporting efficiency gains. - Operational challenges caused minor revenue deferrals in Q3, with Q4 projected to show improved performance. - New biologics contract research and development services to commercialize from Q1 FY '27; revenues expected to start small initially. - Firm focus on expanding laboratory capacities and new testing chambers to support growth. - ROCE expected to normalize back above 20% following current investment phase. - Export revenues growing, with approx.
From Vimta Labs Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Vimta Labs is confident about good near-term and long-term growth due to favorable markets in pharma, food testing, preclinical and clinical research, and electronics testing.
- The company does not provide specific forward-looking revenue numbers but remains optimistic about growth.
- The target of INR 500 crores revenue for the next fiscal year remains aligned.
- Q4 is expected to witness higher revenues, supporting growth trajectory.
- Capacity expansions, including doubling electronics and electrical testing capacity, aim to support sales growth.
- New service lines like biologics contract research and development services are expected to commercialize from Q1 FY ‘27, contributing to future revenue.
- Increasing marketing efforts overseas and adding laboratory facilities will further enable growth.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Vimta Labs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Vimta Labs is continuing to invest in capacity expansion, especially to support growth in defense-related EMI/EMC testing, adding a qualified new chamber recently.
- To sustain growth, the company plans to open more laboratories in the future.
- Recent capex has included significant infrastructure expansion and new biologics, formulation, and process development services.
- Equipment procurement and facility setup for biologics contract research and development services are on track, with commercialization expected by Q1 FY '27.
- Capex typically aligns with depreciation from the previous year to avoid technological obsolescence and support revenue growth.
2 more points management made on capital expenditure plans
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Vimta Labs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has initiated new projects, with one already underway and another in the initiation phase, but their current revenue impact is minimal as the projects are recent.
- Clinical trial bookings experienced some lag in the quarter, leading to deferred revenues.
- Biologics contract research and development services are gearing up, with commercialization expected by Q1 FY '27, though no significant revenues are anticipated immediately.
- Market conditions across pharma, food testing, and electronics testing remain favorable, supporting order book growth.
2 more points management made on order book & pipeline
Vimta Labs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹109 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Vimta Labs Ltd's management said in earlier quarters
- Q3 FY25 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
- Q3 FY23 earnings call →
Others in Healthcare Services this season
- Vijaya Diagnost. (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnost.'s Q3 FY26 earnings call — and…
- Aster DM Quality (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
- Chandan Healthcare Ltd (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
- Rainbow Child. (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
Frequently Asked Questions
What were Vimta Labs Ltd Q3 FY26 results?
Vimta Labs is confident about good near-term and long-term growth due to favorable markets in pharma, food testing, preclinical and clinical research, and electronics testing. Vimta Labs expresses confidence in continued growth driven by favorable market conditions across pharma, food testing, and electronics sectors. - The company targets INR 500 crores revenue for the next fiscal year but refrains from providing firm forward-looking guidance. - EBITDA margins expected to maintain near current levels (±1-2%) with ongoing digital transformation and AI integration supporting efficiency gains. - Operational challenges caused minor revenue deferrals in Q3, with Q4 projected to show improved performance. - New biologics contract research and development services to commercialize from Q1 FY '27; revenues expected to start small initially. - Firm focus on expanding laboratory capacities and new testing chambers to support growth. - ROCE expected to normalize back above 20% following current investment phase. - Export revenues growing, with approx.
What is Vimta Labs Ltd share price analysis?
Vimta Labs Ltd currently shows a neutral. The stock trades at a P/E of 34.1 with a market cap of ₹2,757 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vimta Labs Ltd planning capital expenditure?
Vimta Labs is continuing to invest in capacity expansion, especially to support growth in defense-related EMI/EMC testing, adding a qualified new chamber recently.
Keep Vimta Labs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.